Latest Breaking News On - Full prescribing information - Page 25 : comparemela.com

Seres Therapeutics Announces VOWST™ Commercial Launch Update and US FDA Fast Track Designation for SER-155

VOWST preliminary net sales of approximately $10.4 million for the fourth quarter of 2023 Significant adoption of VOWST since commercial launch in June 2023 through year-end 2023 with 2,833.

Terri youngEric shaffSeres therapeutics incMost influential companiesAimmune therapeutics incExchange commissionHealth scienceSeres therapeuticsTrack designationHealthcare conferenceChief executive officerFast track designationChief commercialStrategy officerTerm loan facilityOaktree capital management

European Commission Approves Pfizer s TALZENNA® in Combination with XTANDI® for Adult Patients with Metastatic Castration-Resistant Prostate Cancer -January 08, 2024 at 10:36 am EST

European Commission Approves Pfizer s TALZENNA® in Combination with XTANDI® for Adult Patients with Metastatic Castration-Resistant Prostate Cancer -January 08, 2024 at 10:36 am EST
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

United statesRobert jonesLab abnormalitiesMedivation incWorld health organization global cancer observatoryEuropean commissionEuropean unionExchange commissionUniversity of glasgowAstellas incProfessor of clinical cancer researchPfizer incClinical cancer researchErik briersVice chairmanHazard ratio

HARMONY BIOSCIENCES PRELIMINARY UNAUDITED FOURTH QUARTER AND FULL YEAR 2023 NET PRODUCT REVENUE INCREASES MORE THAN 30 PERCENT; PROVIDES 2024 NET PRODUCT REVENUE GUIDANCE

/PRNewswire/ Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today reported preliminary, unaudited fourth quarter and full year 2023 net product revenue.

United statesLuis sanayJeffreym daynoDrug administrationParagon biosciencesZynerba pharmaceuticalsExchange commissionPrnewswire harmony biosciences holdings incShare repurchase programPreliminary net revenueFourth quarterFull yearRepresenting growthProduct revenue projected betweenCommon stock repurchaseFourth quarter bringing

Travere Therapeutics Provides Corporate Update and 2024 Outlook

Received 459 new patient start forms for FILSPARI® in the fourth quarter of 2023; preliminary net product sales of FILSPARI totaled $15 million for the fourth quarter Company on track to submit.

Deric dubeExchange commissionEuropean unionProgram updatesCommittee for medicinal products human useTravere therapeutics incTravere therapeuticsNew drug applicationMedicinal productsHuman useConditional marketing authorizationKidney disease improving global outcomesClinical practice guidelineFocal segmental glomerulosclerosisImportant safety informationEndothelin receptor antagonists

Rigel Pharmaceuticals Provides Business Update

/PRNewswire/ Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today provided a business update including preliminary total revenue for the fourth quarter of 2023,.

South san franciscoUnited statesDavid rosenRaul rodriguezKissei pharmaceutical co ltdExchange commissionEuropean medicines agencyPrnewswire rigel pharmaceuticals incAmerican society of hematology annual meetingRigel pharmaceuticals incAmerican cancer societyPreliminary financialMedison pharma tradingCancer centerAmerican societyHematology annual meeting